⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMUX News
Immunic, Inc. Common Stock
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
prnewswire.com
PFE
MRK
LLY
AMGN
BMY
NVS
GILD
AZN
REGN
SNY
TEVA
IMUX
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE
Form 8-K
sec.gov
IMUX
Immunic to Participate in Investor Conferences in July
prnewswire.com
IMUX
Form 8-K
sec.gov
IMUX
Form 8-K
sec.gov
IMUX
Immunic to Participate in Investor, Industry and Scientific Conferences in June
prnewswire.com
IMUX
Form 8-K
sec.gov
IMUX
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
prnewswire.com
IMUX